REPL — Replimune Group Inc
NASDAQ · Healthcare · Biotechnology
$15.67
+$0.37 (+2.42%)
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ. It is led by Sushil Patel Ph.D., based in 500 Unicorn Park Drive, Woburn, MA, United States, 01801, with about 479 employees. Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Net income was -$169.8M. REPL currently screens at market cap $825.7M.
Use this REPL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the REPL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the REPL SEC filings page. Lician reads the product cache first so this HTML stays unique to Replimune Group Inc even when a live quote feed is slow.
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
REPL Key Statistics
Market Cap
$825.73M
Volume
942,435
Previous Close
$14.71
Day Range
$14.60 – $15.46
P/B Ratio
3.44
EPS
-$3.07
Revenue
$0.00
Net Income
-$247.30M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
479
REPL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$247.30M | -$215.79M | -$174.28M | -$118.04M |
| EPS (Diluted) | -$3.07 | -$3.24 | -$2.99 | -$2.26 |
Total Assets
$551.33M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$111.12M
Operating Cash Flow
-$192.25M
Free Cash Flow
$0.00
Replimune Group Inc Company Information
- CEO & Director
- Sushil Patel Ph.D.
- Headquarters
- 500 Unicorn Park Drive, Woburn, MA, United States, 01801
- Website
- www.replimune.com
- Phone
- 781 222 9600
- IPO / Founded
- 2018-07-20
- Sector
- Healthcare
- Industry
- Biotechnology